NeuroSense Therapeutics Ltd.
NRSN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875091
No open-market purchases or sales by NeuroSense Therapeutics Ltd. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $285.7K in total; no superinvestor holds it.
Other share classesNRSNW
Q4 2025 vs. Q3 2025
How the institutions holding NeuroSense Therapeutics Ltd. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 10 | 13 | +3 |
| Shares | 277.9K | 346.1K | +68.2K (+24.5%) |
| Value | $346.8K | $266.2K | −$80.6K (−23.2%) |
New holders (5)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Yorkville Advisors Global, LP | 100,000 | $76.9K | 0.05% |
| GTS Securities LLC | 35,753 | $27.5K | 0.00% |
| Pathstone Holdings, LLC | 16,528 | $12.7K | 0.00% |
| Creative Planning | 11,911 | $9.16K | 0.00% |
| Jessup Wealth Management, Inc | 500 | $385 | 0.00% |
Sold out (2)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Morgan Stanley | 66,400 | $83.0K |
| CWM, LLC | 1,000 | $1.00K |